ABL1 and acute lymphoblastic leukemia: Imatinib is a tyrosine kinase inhibitor (TKI) against BCR-ABL1 fusion tyrosine kinase derived from Philadelphia chromosome in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)1,2.